- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04681820
Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib
Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning or Failure) to Imatinib or Dasatinib: A Prospective, Multicenter, Pragmatic Clinical Trial
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Weiming Li
- Phone Number: 13098815546
- Email: liweiming202012@163.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China
- Recruiting
- Weiming Li
-
Contact:
- Ming Wei Li
- Phone Number: 13098815546
- Email: liweiming202012@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male or female patients ≥18 years of age;
CML-CP patients when enrolled
Definition of diagnosis:
Bone marrow cytogenetic confirmation of Philadelphia chromosome of t (9;22) translocations and/or the presence of P210 BCR-ABL1 transcripts via molecular assessment;
Documented chronic phase CML will meet all the criteria defined as:
< 15% blasts in peripheral blood and bone marrow < 30% blasts plus promyelocytes in peripheral blood and bone marrow < 20% basophils in the peripheral blood
≥ 100 x 109/L (≥ 100,000/mm3) platelets No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly
- CML-CP patients without optimal response(warning or failure) when treated with imatinib or dasatinib.
- Female patients of childbearing potential must have a negative serum pregnancy test;
- Ability to provide written informed consent prior to any study related screening procedures being performed.
Exclusion Criteria:
- Treatment with other tyrosine kinase inhibitor(s) except imatinib and dasatinib prior to study entry;
- With any mutations as follows :T315I、Y253F/H、E255K/V、F359C/V/I (if there are any other mutations,at physicians' discretion );
- Entry into another therapeutic clinical trial;
- Concomitant diseases that, according to the investigator's judgment, pose a serious risk to the patient's safety or completion of the study;
- History of neurological or psychiatric disorders, including epilepsy or dementia;
- Major surgery within 4 weeks prior to Day 1 of study;
- Patients with another primary malignancy,unless the other primary malignancy is currently stable or does not need active intervention;
- Women of reproductive age or men who are unable to use adequate methods of contraception, including women who are pregnant or breastfeeding;
- ECOG≥3;
- Patients who are unable to compliance with study or follow-up procedures;
- Allergic to any of the components in this trial;
- Not appropriate to attend this trial judged by the investigator.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
flumatinib
flumatinib 600mg QD, fasting administration
|
Flumatinib mesylate tablets 600mg qd for 24 months
Nilotinib Capsules 400mg bid for 24 months
|
nilotinib
nilotinib 400mg BID, fasting administration
|
Flumatinib mesylate tablets 600mg qd for 24 months
Nilotinib Capsules 400mg bid for 24 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major molecular response rate at 12 months
Time Frame: 12 months
|
Major molecular response is defined as ≤ 0.1% BCR-ABL/ABL% by international scale
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease Attributes
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia
- Leukemia, Myeloid
- Chronic Disease
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Flumatinib
Other Study ID Numbers
- HS-2020-07WH
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CML-CP; Mutation;Suboptimal Response or Failure in TKI
-
Roswell Park Cancer InstituteActive, not recruitingAcute Myeloid Leukemia | Polycythemia Vera | Myelofibrosis | Chronic Myelomonocytic Leukemia | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Sickle Cell Disease | Myelodysplastic Syndrome | Plasma Cell Myeloma | Chronic Granulomatous... and other conditionsUnited States
Clinical Trials on Flumatinib
-
The First Affiliated Hospital of Soochow UniversityRecruitingCML, Chronic Phase; TKIChina
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Recruiting
-
Shenzhen Second People's HospitalHainan General Hospital; Sanya Central Hospital; First Affiliated Hospital of... and other collaboratorsRecruitingChronic Myeloid Leukemia, Chronic Phase | Flumatinib | ImatinibChina
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Not yet recruiting
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.UnknownChronic Myelogenous LeukemiaChina
-
Shenzhen Second People's HospitalRecruitingChronic Myeloid Leukemia in Chronic PhaseChina
-
Ferring PharmaceuticalsCompletedMenorrhagia | Heavy Menstrual BleedingUnited States
-
wang, jianxiangRecruiting
-
Zhongda HospitalRecruitingBCR-ABL1 Fusion Protein Expression | Acute Lymphocytic Leukemia, Adult B-CellChina
-
University Hospital, LimogesCompleted